A 2017 study, identified by plate number KAT301, sought to evaluate the safety, myocardial perfusion, angina pectoris, and quality of life of refractory angina patients who received targeted intramyocardial gene VEGF-DΔNΔC therapy with an adenoviral vector. Here, VEGFA is linked to angina pectoris.